Estimating Australian Population Utilities for Inherited Retinal Disease Using Time Trade-Off
This study provides valuable information on HSUs across a range of IRD health states from the Australian general population perspective. The utilities obtained in this study can be used as inputs into CUA of IRD therapies.
Authors
- Milena Lewandowska (ORCID: https://orcid.org/0000-0002-9068-9504)
- Elena Meshcheriakova (ORCID: https://orcid.org/0000-0003-4411-204X)
- Kathleen Manipis (ORCID: https://orcid.org/0000-0002-7159-0912)
- Stephen Goodall (ORCID: https://orcid.org/0000-0001-6611-6565)
- Maria Farris (ORCID: https://orcid.org/0000-0003-3542-7162)
- Richard De Abreu Lourenço (ORCID: https://orcid.org/0000-0002-5978-8774)
- Brendan Mulhern (ORCID: https://orcid.org/0000-0003-3656-8063)
Institutions
- University of Technology Sydney (AU)
- Australian Hearing (AU)
- Novartis (Australia) (AU)
- Teva Pharmaceuticals (Australia) (AU)
Publication Details
- Journal
- PharmacoEconomics - Open
- Published
- 2024-08-05
- DOI
- https://doi.org/10.1007/s41669-024-00515-5
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Novartis Australia